Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LNPEP | Q9UIQ6 | 5/20 | 0.54 |
| ▸ | ERAP2 | Q6P179 | 4/20 | 0.54 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.53 |
| ▸ | HPGDS | O60760 | 1/20 | 0.50 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.49 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | PYGL | P06737 | 1/20 | 0.46 |
| ▸ | PLG | P00747 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22312697 | 0.91 | ITGB3 (0.55) | LNPEPERAP2ERAP1HPGDSC3AR1 | |
| SCHEMBL6810961 | 0.91 | ITGB3 (0.55) | LNPEPERAP2ERAP1HPGDSC3AR1 | |
| SCHEMBL7390292 | 0.91 | ITGB3 (0.55) | LNPEPERAP2ERAP1HPGDSC3AR1 | |
| SCHEMBL607886 | 0.88 | ITGB3 (0.60) | LNPEPERAP2ERAP1HPGDSC3AR1 | |
| SCHEMBL607885 | 0.88 | ITGB3 (0.60) | LNPEPERAP2ERAP1HPGDSC3AR1 | |
| Hydrochloric Acid SCHEMBL2331400 | 0.86 | LNPEP (0.53) | LNPEPERAP2ERAP1HPGDSC3AR1 | |
| SCHEMBL10374327 | 0.86 | LNPEP (0.53) | LNPEPERAP2ERAP1HPGDSC3AR1 | |
| SCHEMBL29504058 | 0.85 | LNPEP (0.52) | LNPEPERAP2ERAP1HPGDSC3AR1 | |
| SCHEMBL1980652 | 0.83 | ITGB3 (0.57) | LNPEPERAP2ERAP1HPGDSC3AR1 | |
| SCHEMBL1980150 | 0.83 | ITGB3 (0.57) | LNPEPERAP2ERAP1HPGDSC3AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0692982-B1 | RADIOLABELED PLATELET GPIIb/IIIa RECEPTOR ANTAGONISTS AS IMAGING AGENTS FOR THE DIAGNOSIS OF THROMBOEMBOLIC DISORDERS | DU PONT PHARM CO (US) | 2000-07-05 | — | — | EP | claimed |
| EP-0995761-A2 | Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders | Dupont Pharmaceuticals Company (US) | 2000-04-26 | — | — | EP | claimed |
| US-6818659-B2 | TARGETS AND BINDS BIOLOGICAL RECEPTORS; MEDICAL DIAGNOSIS; MAGNETIC RESONANCE, X-RAY, ULTRASOUND, AND CONTRAST IMAGING | BRISTOL-MYERS SQUIBB PHARMA, INC. | 2004-11-16 | — | — | US | disclosed |
| US-20040087603-A1 | (2S) -2-AMINO-4-(2-AMINO-(3,4,5,6-TETRAHYDROPYRIMIDIN-4-YL) BUTANOYL AND ITS USE IN CYCLIC AND ACYCLIC PEPTIDES | LANTHEUS MEDICAL IMAGING, INC. | 2004-05-06 | — | — | US | disclosed |
| EP-0692982-B1 | RADIOLABELED PLATELET GPIIb/IIIa RECEPTOR ANTAGONISTS AS IMAGING AGENTS FOR THE DIAGNOSIS OF THROMBOEMBOLIC DISORDERS | DU PONT PHARM CO (US) | 2000-07-05 | — | — | EP | disclosed |
| EP-0995761-A2 | Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders | Dupont Pharmaceuticals Company (US) | 2000-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087603-A1 | (2S) -2-AMINO-4-(2-AMINO-(3,4,5,6-TETRAHYDROPYRIMIDIN-4-YL) BUTANOYL AND ITS USE IN CYCLIC AND ACYCLIC PEPTIDES | VIP, ARGLU1, NGLY1 | LNPEP 9/4885ERAP2 191/4885ERAP1 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.